Published in Antimicrob Agents Chemother on February 01, 2005
The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nat Rev Microbiol (2009) 8.13
Confronting the scientific obstacles to global control of tuberculosis. J Clin Invest (2008) 4.41
Drug tolerance in replicating mycobacteria mediated by a macrophage-induced efflux mechanism. Cell (2011) 3.42
Cytological and transcript analyses reveal fat and lazy persister-like bacilli in tuberculous sputum. PLoS Med (2008) 3.01
Why is long-term therapy required to cure tuberculosis? PLoS Med (2007) 2.03
Characterization and transcriptome analysis of Mycobacterium tuberculosis persisters. MBio (2011) 1.64
New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development. Antimicrob Agents Chemother (2008) 1.50
Use of nonlinear mixed-effects analysis for improved precision of early pharmacodynamic measures in tuberculosis treatment. Antimicrob Agents Chemother (2006) 1.10
Assessment of the Efficacy of New Anti-Tuberculosis Drugs. Open Infect Dis J (2008) 0.91
New insights into TB physiology suggest untapped therapeutic opportunities. Immunol Rev (2015) 0.83
Mycobacterium tuberculosis Is Resistant to Isoniazid at a Slow Growth Rate by Single Nucleotide Polymorphisms in katG Codon Ser315. PLoS One (2015) 0.82
Antituberculosis therapy for 2012 and beyond. Expert Opin Pharmacother (2012) 0.80
Granuloma transplantation: an approach to study mycobacterium-host interactions. Front Microbiol (2011) 0.78
Docking studies on novel analogues of 8 methoxy fluoroquinolones against GyrA mutants of Mycobacterium tuberculosis. BMC Struct Biol (2011) 0.76
Chemotherapeutic interventions against tuberculosis. Pharmaceuticals (Basel) (2012) 0.75
Novel imidazoline antimicrobial scaffold that inhibits DNA replication with activity against mycobacteria and drug resistant Gram-positive cocci. ACS Chem Biol (2014) 0.75
A Flow Cytometry Method for Rapidly Assessing Mycobacterium tuberculosis Responses to Antibiotics with Different Modes of Action. Antimicrob Agents Chemother (2016) 0.75
A selective oleic acid albumin agar medium for tubercle bacilli. J Med Microbiol (1972) 6.78
The early bactericidal activity of drugs in patients with pulmonary tuberculosis. Am Rev Respir Dis (1980) 4.69
Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days. Am J Respir Crit Care Med (2003) 4.36
Role of individual drugs in the chemotherapy of tuberculosis. Int J Tuberc Lung Dis (2000) 2.94
Two 8-month regimens of chemotherapy for treatment of newly diagnosed pulmonary tuberculosis: international multicentre randomised trial. Lancet (2004) 2.84
Sterilizing activities of fluoroquinolones against rifampin-tolerant populations of Mycobacterium tuberculosis. Antimicrob Agents Chemother (2003) 2.34
Experimental models to explain the high sterilizing activity of rifampin in the chemotherapy of tuberculosis. Am Rev Respir Dis (1981) 2.31
In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis. Int J Antimicrob Agents (2002) 2.07
The Garrod Lecture. Understanding the chemotherapy of tuberculosis--current problems. J Antimicrob Chemother (1992) 1.87
Bactericidal action of ofloxacin, sulbactam-ampicillin, rifampin, and isoniazid on logarithmic- and stationary-phase cultures of Mycobacterium tuberculosis. Antimicrob Agents Chemother (1996) 1.48
The bactericidal activities of antituberculous drugs. Am Rev Tuberc (1956) 1.41
Development of fluoroquinolones as first-line drugs for tuberculosis--at long last! Am J Respir Crit Care Med (2003) 1.09
Gatifloxacin and ethionamide as the foundation for therapy of tuberculosis. Antimicrob Agents Chemother (2003) 1.05
Clinical pharmacology of gatifloxacin, a new fluoroquinolone. Clin Infect Dis (2000) 1.01
Fluoroquinolones in the treatment of tuberculosis: a study in mice. Am J Respir Crit Care Med (2004) 0.83
Advances in techniques of testing mycobacterial drug sensitivity, and the use of sensitivity tests in tuberculosis control programmes. Bull World Health Organ (1969) 12.55
A selective oleic acid albumin agar medium for tubercle bacilli. J Med Microbiol (1972) 6.78
Antigenic diversity of Mycobacterium tuberculosis and Mycobacterium bovis detected by means of monoclonal antibodies. Lancet (1981) 6.01
The early bactericidal activity of drugs in patients with pulmonary tuberculosis. Am Rev Respir Dis (1980) 4.69
Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications. Int J Tuberc Lung Dis (1999) 4.52
A Phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis (2008) 3.77
The action of antituberculosis drugs in short-course chemotherapy. Tubercle (1985) 3.69
Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis. Am Rev Respir Dis (1986) 3.46
Timing of relapse in short-course chemotherapy trials for tuberculosis. Int J Tuberc Lung Dis (2010) 3.07
Assessment of new sterilizing drugs for treating pulmonary tuberculosis by culture at 2 months. Am Rev Respir Dis (1993) 3.01
Socio-economic impact of tuberculosis on patients and family in India. Int J Tuberc Lung Dis (1999) 2.70
Site-directed alkylation and the alternating access model for LacY. Proc Natl Acad Sci U S A (2006) 2.65
Sulphadimidine acetylation test for classification of patients as slow or rapid inactivators of isoniazid. Br Med J (1970) 2.61
Selective Kirchner medium in the culture of specimens other than sputum for mycobacteria. J Clin Pathol (1983) 2.61
Short-course chemotherapy for pulmonary tuberculosis. Am Rev Respir Dis (1975) 2.59
The use of murine monoclonal antibodies without purification of antigen in the serodiagnosis of tuberculosis. J Immunol Methods (1982) 2.57
Quality control in tuberculosis bacteriology. 1. Laboratory studies on isolated positive cultures and the efficiency of direct smear examination. Tubercle (1980) 2.57
Experimental models to explain the high sterilizing activity of rifampin in the chemotherapy of tuberculosis. Am Rev Respir Dis (1981) 2.31
Selective media in the isolation of tubercle bacilli from tissues. J Clin Pathol (1973) 2.17
The early bactericidal activity of rifabutin in patients with pulmonary tuberculosis measured by sputum viable counts: a new method of drug assessment. J Antimicrob Chemother (1993) 2.12
Detection of mRNA transcripts and active transcription in persistent Mycobacterium tuberculosis induced by exposure to rifampin or pyrazinamide. J Bacteriol (2000) 2.03
Basic mechanisms of chemotherapy. Chest (1979) 2.01
Controlled clinical trial of complete open surgical drainage and of prednisolone in treatment of tuberculous pericardial effusion in Transkei. Lancet (1988) 1.99
Preventive chemotherapy of tuberculosis in Cornell model mice with combinations of rifampin, isoniazid, and pyrazinamide. Antimicrob Agents Chemother (1996) 1.97
Application of DNA fingerprinting with IS986 to sequential mycobacterial isolates obtained from pulmonary tuberculosis patients in Hong Kong before, during and after short-course chemotherapy. Tuber Lung Dis (1993) 1.94
A multicentre study of the early bactericidal activity of anti-tuberculosis drugs. J Antimicrob Chemother (2000) 1.90
A computer-assisted bacteriology reporting and information system. J Clin Pathol (1978) 1.86
A pilot study on willingness to participate in future preventive HIV vaccine trials. Indian J Med Res (2006) 1.85
The early bactericidal activity of isoniazid related to its dose size in pulmonary tuberculosis. Am J Respir Crit Care Med (1997) 1.76
Rifapentine and isoniazid in the continuation phase of a 6-month regimen. Final report at 5 years: prognostic value of various measures. Int J Tuberc Lung Dis (2002) 1.73
An effective method of RNA extraction from bacteria refractory to disruption, including mycobacteria. Nucleic Acids Res (1997) 1.69
Primary drug resistance in pulmonary tuberculosis in Great Britain: second national survey, 1963. Tubercle (1966) 1.65
Malabsorption of rifampin and isoniazid in HIV-infected patients with and without tuberculosis. Clin Infect Dis (2003) 1.63
Activity in vitro of rifabutin, FCE 22807, rifapentine, and rifampin against Mycobacterium microti and M. tuberculosis and their penetration into mouse peritoneal macrophages. Am Rev Respir Dis (1992) 1.56
The correlation of bacteriophage types of Mycobacterium tuberculosis with guinea-pig virulence and in vitro-indicators of virulence. J Gen Microbiol (1978) 1.55
Comparison of phenotypic and genotypic methods for pyrazinamide susceptibility testing with Mycobacterium tuberculosis. J Clin Microbiol (2000) 1.51
Bactericidal activity of streptomycin, isoniazid, rifampin, ethambutol, and pyrazinamide alone and in combination against Mycobacterium Tuberculosis. Am Rev Respir Dis (1977) 1.50
Protein synthesis is shutdown in dormant Mycobacterium tuberculosis and is reversed by oxygen or heat shock. FEMS Microbiol Lett (1998) 1.48
Bactericidal action of ofloxacin, sulbactam-ampicillin, rifampin, and isoniazid on logarithmic- and stationary-phase cultures of Mycobacterium tuberculosis. Antimicrob Agents Chemother (1996) 1.48
Bioavailability of rifampin in experimental murine tuberculosis. Antimicrob Agents Chemother (1992) 1.48
Suitability of rifampicin for intermittent administration in the treatment of tuberculosis. Tubercle (1970) 1.45
Bioavailability of Chinese rifapentine during a clinical trial in Hong Kong. Int J Tuberc Lung Dis (1997) 1.44
Decreased bioavailability of rifampin and other antituberculosis drugs in patients with advanced human immunodeficiency virus disease. Antimicrob Agents Chemother (2004) 1.44
Suitability of isoniazid and ethambutol for intermittent administration in the treatment of tuberculosis. Tubercle (1968) 1.43
Observations in vitro on the suitability of pyrazinamide for intermittent chemotherapy of tuberculosis. Tubercle (1970) 1.41
Drug resistance in mycobacteria. Br Med Bull (1984) 1.40
Rifabutin in the treatment of newly diagnosed pulmonary tuberculosis. Tuber Lung Dis (1995) 1.39
HLA typing in the Hong Kong Chest Service/British Medical Research Council study of factors associated with the breakdown to active tuberculosis of inactive pulmonary lesions. Am Rev Respir Dis (1988) 1.38
Larvicidal activity of some Euphorbiaceae plant extracts against Aedes aegypti and Culex quinquefasciatus (Diptera: Culicidae). Parasitol Res (2007) 1.38
Quality control in tuberculosis bacteriology. 2. The origin of isolated positive cultures from the sputum of patients in four studies of short course chemotherapy in Africa. Tubercle (1980) 1.36
In vitro activity of new rifamycins against rifampicin-resistant M. tuberculosis and MAIS-complex mycobacteria. Tubercle (1987) 1.35
Early bactericidal activity of ethambutol, pyrazinamide and the fixed combination of isoniazid, rifampicin and pyrazinamide (Rifater) in patients with pulmonary tuberculosis. S Afr Med J (1996) 1.34
The bacterial DNA content of mouse organs in the Cornell model of dormant tuberculosis. Tuber Lung Dis (1995) 1.33
Synaptic and neurotransmitter activation of cardiac vagal neurons in the nucleus ambiguus. Ann N Y Acad Sci (2001) 1.32
In vitro observations on the suitability of new rifamycins for the intermittent chemotherapy of tuberculosis. Tubercle (1987) 1.30
Risk of development of tuberculosis in HIV-infected patients. Int J Tuberc Lung Dis (2000) 1.28
Laboratory aspects of intermittent drug therapy. Postgrad Med J (1971) 1.28
Metronidazole has no antibacterial effect in Cornell model murine tuberculosis. Int J Tuberc Lung Dis (1998) 1.28
The early bactericidal activity of ciprofloxacin in patients with pulmonary tuberculosis. Am J Respir Crit Care Med (1997) 1.27
Amikacin in the treatment of pulmonary tuberculosis. Tubercle (1983) 1.23
Examination of sputum by smear and culture in case-finding. Bull Int Union Tuberc (1968) 1.23
Geographic distribution of bacteriophage types of Mycobacterium tuberculosis. Am Rev Respir Dis (1969) 1.23
Role of pneumococcal antigen in the diagnosis of pneumococcal pneumonia. Thorax (1992) 1.22
Sterilising action of pyrazinamide in models of dormant and rifampicin-tolerant Mycobacterium tuberculosis. Int J Tuberc Lung Dis (2006) 1.20
Rifapentine and isoniazid in the continuation phase of treating pulmonary tuberculosis. Initial report. Am J Respir Crit Care Med (1998) 1.20
In vitro properties of rifapentine (MDL473) relevant to its use in intermittent chemotherapy of tuberculosis. Tubercle (1987) 1.19
The therapy of pulmonary tuberculosis in Kenya: a comparison of the results achieved in controlled clinical trials with those achieved by the routine treatment services. Tubercle (1970) 1.18
Isolation and Identification of Environmental Mycobacteria in the Mycobacterium bovis BCG Trial Area of South India. Appl Environ Microbiol (1994) 1.16
Comparison of machine and manual staining of direct smears for acid-fast bacilli by fluorescence microscopy. J Clin Pathol (1976) 1.16
Evaluation of PCR using TRC(4) and IS6110 primers in detection of tuberculous meningitis. J Clin Microbiol (2001) 1.13
Rifampin-induced release of hydrazine from isoniazid. A possible cause of hepatitis during treatment of tuberculosis with regimens containing isoniazid and rifampin. Am Rev Respir Dis (1986) 1.13
Role of lipid content and hydrogen peroxide susceptibility in determining the guinea-pig virulence of Mycobacterium tuberculosis. Br J Exp Pathol (1982) 1.13
Bioavailability of rifampicin, isoniazid and pyrazinamide in a triple drug formulation: comparison of plasma and urine kinetics. Int J Tuberc Lung Dis (1999) 1.12
Effects of recombinant interferon-gamma and chemotherapy with isoniazid and rifampicin on infections of mouse peritoneal macrophages with Listeria monocytogenes and Mycobacterium microti in vitro. Br J Exp Pathol (1986) 1.12
Evaluation of procedures for isolation of nontuberculous mycobacteria from soil and water. Appl Environ Microbiol (1994) 1.12
Simple and rapid liquid chromatography method for determination of efavirenz in plasma. J Chromatogr B Analyt Technol Biomed Life Sci (2006) 1.12
The early bactericidal activity of rifabutin measured by sputum viable counts in Hong Kong patients with pulmonary tuberculosis. Tuber Lung Dis (1992) 1.11
Bactericidal activity in vitro and in the guinea-pig of isoniazid, rifampicin and ethambutol. Tubercle (1976) 1.10
Unrecognised tuberculosis in HIV-infected patients: sputum culture is a useful tool. Int J Tuberc Lung Dis (2004) 1.09
Long term follow up of HIV-infected patients with tuberculosis treated with 6-month intermittent short course chemotherapy. Natl Med J India (2008) 1.09
Pyrazinamide and other drugs in tuberculous meningitis. Lancet (1973) 1.09
Examination of operation specimens from patients with spinal tuberculosis for tubercle bacilli. J Clin Pathol (1983) 1.08
Comparison of methods for testing the sensitivity of Mycobacterium tuberculosis to ethionamide. Tubercle (1966) 1.08
Factors associated with willingness to participate in HIV vaccine trials among high-risk populations in South India. AIDS Res Hum Retroviruses (2009) 1.08
Isolation and identification of mosquito larvicidal compound from Abutilon indicum (Linn.) Sweet. Parasitol Res (2008) 1.07
Antibiotic resistance in common acute respiratory pathogens. Thorax (1995) 1.07
Standard smears for grading the content of acid-fast bacilli in sputum. Tubercle (1966) 1.07
Hemagglutination tests for tuberculosis with mycobacterial glycolipid antigens. Results in patients with active pulmonary tuberculosis before and during chemotherapy and in healthy tuberculosis contacts. Am Rev Respir Dis (1981) 1.06
Action of metronidazole in combination with isoniazid & rifampicin on persisting organisms in experimental murine tuberculosis. Indian J Med Res (1998) 1.06
Demonstration of increased anti-mycobacterial activity in peripheral blood monocytes after BCG vaccination in British school children. Clin Exp Immunol (1988) 1.05
Recombinant interferon-gamma and chemotherapy with isoniazid and rifampicin in experimental murine tuberculosis. Br J Exp Pathol (1986) 1.05
Activity of two long-acting rifamycins, rifapentine and FCE 22807, in experimental murine tuberculosis. Tuber Lung Dis (1992) 1.04
Pulmonary function in healthy young adult Indians in Madras. Thorax (1990) 1.04
Response to treatment with isoniazid plus PAS of tuberculous patients with primary isoniazid resistance. Tubercle (1969) 1.03
Counts of viable tubercle bacilli in sputum related to smear and culture gradings. Med Lab Sci (1992) 1.02
Moxifloxacin and gatifloxacin in an acid model of persistent Mycobacterium tuberculosis. J Chemother (2006) 1.02